[1]王佳蓉 邱连升 陈翊民 陈敏云.舌下含服标准化尘螨滴剂治疗儿童变应性鼻炎的疗效及机制研究[J].福建医药杂志,2020,42(01):19-22.
　WANG Jiarong,QIU Liansheng,CHEN Yimin,et al.Research on the efficacy and mechanism of sublingual standardized dust mite drops allergen vaccine to allergic rhinitis in children[J].FUJIAN MEDICAL JOURNAL,2020,42(01):19-22.
点击复制

舌下含服标准化尘螨滴剂治疗儿童变应性鼻炎的疗效及机制研究()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期数:
2020年01期
页码:
19-22
栏目:
临床研究
出版日期:
2020-03-30

文章信息/Info

Title:
Research on the efficacy and mechanism of sublingual standardized dust mite drops allergen vaccine to allergic rhinitis in children
文章编号:
1002-2600(2020)01-0019-04
作者:
王佳蓉 邱连升1 陈翊民 陈敏云
福建医科大学附属第二医院耳鼻咽喉科(泉州 362000)
Author(s):
WANG Jiarong; QIU Liansheng; CHEN Yimin; CHEN Minyun.
Department of Otorhinolaryngology, the Second Affiliated hospital of Fujian Medical University, Quanzhou,Fujian 362000, China
关键词:
鼻炎; 变应性; 持续性;  脱敏法; 免疫;  T淋巴细胞; 调节性;  Thl7细胞
Keywords:
rhinitis; allergic; persistent;  desensitization;  immunologic;  T-lymphocytes; regulatory;  Thl7 cells
分类号:
R765
文献标志码:
B
摘要:
目的 探讨舌下含服标准化尘螨滴剂特异性免疫(SLIT)治疗儿童变应性鼻炎(AR)的疗效和可能机制。方法 选取我院确诊为持续性变应性鼻炎的患儿80例,根据患儿家属意愿分为标准化尘螨滴剂舌下含服特异性免疫治疗组(观察组)与常规药物治疗(对照组),每组40例。采用症状视觉模拟量表评分(VAS)、用药评分法评定疗效,比较治疗前与治疗1年后的VAS评分与用药评分。采用流体细胞技术检测治疗前、治疗1年后外周血辅助性T细胞17(Th17)、调节性T细胞(Treg)的细胞比例。 结果 观察组治疗1年后VAS评分及用药评分分别为(2.70±1.08)、(1.05±0.81),较治疗前的(7.65±1.23)、(3.58±0.96)明显下降,差异均有统计学意义(t=31.35,t=13.83; 均P<0.05)。对照组治疗1年后VAS评分为(3.34±1.22),较治疗前的(7.35±1.03)下降,差异有统计学意义(t=14.64,P<0.05); 对照组治疗前后用药评分差异无统计学意义(t=0.80,P=0.43)。观察组治疗1年后外周血Treg细胞比例显著增高,Th17细胞比例降低,差异有统计学意义(tTreg=20.28,tTh17=9.41,均P<0.05),而对照组治疗前后Treg和Th17细胞比例差异无统计学意义(均P>0.05)。结论 两组均能改善AR 患者症状,而SLIT 能减少患儿药物用量,其疗效优于常规药物治疗。SLIT治疗AR的机制可能是能够诱导Treg细胞的产生,抑制Thl7细胞增殖,上调Treg/Thl7比例,使Treg和Thl7细胞亚群比例和功能的平衡复位,最终达到免疫耐受。
Abstract:
Objective The study was designed to analyze the efficacy and investigate the possible mechanism of sublingual standardized dust mite drops allergen vaccine to allergic rhinitis(AR)in children.Methods The study was performed in the Second Affiliated hospital of Fujian Medical University, involving 80 children patients with persistent AR,of whom 40 children patients received sublingual immunotherapy(SLIT)and pharmacotherapy(observation group)after their guardians, approval and 40 children patients received only pharmacotherapy(control group).All patients were allergic to dust mites.Symptom and medication scores were recorded before treatment and after treatment one year. Treg cells and Thl7 cells were measured by flow cytometry.Results VAS score and medication score in the observation group after one year of treatment were(2.70±1.08)and(1.05±0.81), respectively, which were significantly lower than those before treatment(7.65±1.23)and(3.58±0.96), with statistically significant differences(t=31.35, t=13.83).All P<0.05).The VAS score in the control group was(3.34±1.22)after one year of treatment, which was lower than that before treatment(7.35±1.03), and the difference was statistically significant(t=14.64, P<0.05),and there was no significant difference in medication scores before and after treatment(t=0.80, P=0.43). The proportion of Thl7 cells in peripheral blood mononuclear cells decreased in the observation group, whereas the proportion of Treg cells increased(tTreg=20.28,tTh17=9.41; both P<0.05),but not in the control group.Conclusion Both SLIT and pharmacotherapy can improve symptoms of AR, but SLIT can also reduce medication use.The effect of immunotherapy is better than drug treatment alone.The proportion of blood Thl7 cells in peripheral blood mononuclear cells decreases in patients treated with SLIT, whereas the proportion of Treg cells increases,the proportion of Treg/Thl7 is upregulated to restore the balance of the proportion and function of Treg and Thl7 cell subsets and finally achieves immune tolerance.

参考文献/References:

[1] 储俊才,程雷.变应性鼻炎变应原免疫治疗新指南[J].中国中西医结合耳鼻咽喉科杂志,2018,26(3):161-162.
[2] 刘莉,刘争,梁耕田,等.Treg/Th17在变应性鼻炎患者血液中的意义[J].现代免疫学,2015,35(2):136- 140.
[3] Gu Z W,Wang Y X,Cao Z W.Neutralization of interleukin-9 ameliorates symptoms of allergic rhinitis by reducing Th2,Th9,and Th17 responses and increasing the Treg response in a murine model [J].Oncotarget, 2017,8(9):14314-14324.
[4] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组.变应性鼻炎诊断和治疗指南(2015 年,天津)[J]. 中华耳鼻咽喉头颈外科杂志,2016,51(1): 6-24.
[5] Bousquet P J,Combescure C, Neukirch F, et al.Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines[J].Allergy,2007,62(4):367-372.
[6] Pfaar O, Demoly P, Gerth van Wijk R, et al.Recommen-dations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper[J],Allergy,2014,69(7):854-867.
[7] 王洁,周丽枫,陈彦秋,等.广州地区儿童变应性鼻炎患者吸入变应原谱分析[J].临床耳鼻咽喉头颈外科杂志,2012,26(22):1026-1029.
[8] 宋薇薇,林小平,仲欢欢,等.辽宁地区变应性鼻炎患者吸入变应原谱分析[J].中华临床免疫和变态反应杂志,2011,5(4):263-267.
[9] Zhang Y M,Zhang J, Liu S L, et al.Prevalence and associated risk factors of allergic rhinitis in preschool children in Beijing [J]. Laryngoscope, 2013,123(1):28-35.
[10] Bao Y, Chen J, Cheng L, et al.Chinese Guideline on allergen immunotherapy for allergic rhinitis [J]. J Thorac Dis, 2017, 9(11): 4607-4650.
[11] Agrawal D K, Shao Z.Pathogenesis of allergic airway inflammation [J].Curr Allergy Asthma Pep, 2010,10(1):39-48.
[12] Wei P,Nu G N,Kang N Y, et al.An aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress the Thl7 response in allergic rhinitis patients [J].Lab 1nvest, 2014, 94(5): 528-535.
[13] 瞿申红,李敏,黄永坚,等.变应原和糖皮质激素对变应性鼻炎患者外周血Thl7细胞及其转录因子RORγt的作用[J].中华耳鼻咽喉头颈外科杂志,2009,44(12):996-1000.
[14] Peterson R A.Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression [J]. Toxicol Pathol, 2012, 40(2): 186-204.
[15] Akdis C A, Akdis M.Mechanisms of allergen-specific immunotherapy [J]. J Allergy Clin Immunol,2011,127(1):18-27.
[16] Meiler F, Klunker S, Zimmermann M, et al.Distinct regula-tion of IgE,IgG4 and IgA by T regulatory cells and toll-like receptors [J]. Allergy, 2008,63(11):1455-1463.

备注/Memo

备注/Memo:
基金项目:福建省自然科学基金资助项目(2016J01521)1 通信作者,Email:bear443@163.com
更新日期/Last Update: 2020-03-30